Aavnergene
- Biotech or pharma, therapeutic R&D
- CMO, CRO
AAVnerGene Inc. is an innovative biotech company founded in 2019 at Rockville, Maryland USA. Six years ago we envisioned problems that AAV gene therapy is facing today, and have been focusing on developing new technologies to solve them.
We developed a novel one-plasmid AAV production system, AAVone, to solve the AAV manufacture problem. AAVone has much higher productivity and quality, simpler protocol and substantially less cost, making AAV gene therapy more accessible and affordable.
AAVnerGene also developed a proprietary AAV capsid engineering platform, ATHENA, to develop highly efficient and specific AAVs solving the high dose and toxicity problems. We have developed new AAVs targeting brain, lung, kidney, eye, T cells with hundreds of folds of higher transduction efficiency. With these AAVs, new pipelines need much less dose, and will reduce toxicity and cost. making AAV gene therapy more effective and appliable for more common diseases.
Collaboration and investment are welcome.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}